RGMP.US Regnum Corp
- Market cap
- USD 2.30K
- P/E
- -
- P/B
- 7,857.73x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is RGMP.US undervalued?
Graham numberThe Graham number of Regnum Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regnum Corp fundamental analysis
No fundamental analysis for Regnum Corp yet.
Regnum Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regnum Corp
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Full company profileRegnum Corp financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regnum Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 18.1K | 21.4K | 6.30K | 9.00K | 9.00K | 0.00 | - |
| Gross Profit | - | 18.1K | 20.8K | 5.94K | 6.77K | 6.77K | 0.00 | - |
| Operating Income | -825.00 | 2.25K | 3.45K | -35.6K | -118K | -368K | -736K | - |
| EBITDA | 275.00 | 2.55K | 4.05K | -35.2K | -113K | -265K | -736K | - |
| Net Income | -825.00 | 1.39K | 2.00K | -36.4K | -118K | -270K | -781K | - |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.03 | - |
| Balance Sheet | ||||||||
| Total Assets | - | 14.8K | 47.7K | 8.48K | 4.50K | 1.49M | 865K | - |
| Total Liabilities | 825.00 | 2.19K | 3.64K | 800.00 | 54.9K | 1.87M | 2.03M | - |
| Shareholders' Equity | -825.00 | 12.6K | 44.1K | 7.68K | -50.4K | -380K | -1.16M | - |
| Cash & Short-term Investments | - | 14.6K | 47.3K | 7.44K | 0.00 | 1.49M | 783K | - |
| Total Debt | - | - | - | - | - | 1.51M | 1.56M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 3.05K | 3.05K | 4.05K | -38.9K | -3.67K | -11.6K | -706K | - |
| Capital Expenditure | 0.00 | 500.00 | 800.00 | 1.00K | 6.00K | 6.00K | 0.00 | 0.00 |
| Free Cash Flow | - | 2.55K | 3.25K | -39.9K | -9.67K | -11.6K | -706K | - |
| Ratios | ||||||||
| ROE | - | 11.0% | 4.5% | -473.7% | - | - | - | - |
| ROA | - | 9.4% | 4.2% | -429.0% | -2,615.0% | -18.1% | -90.3% | - |
| Net Profit Margin | - | 7.7% | 9.3% | -577.5% | -1,307.5% | -3,000.0% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Regnum Corp dividends
Regnum Corp has not paid dividends in the last 7 fiscal years.
Who owns Regnum Corp
- Insiders 98.82%
- Institutions 0.00%
- Public & others 1.18%
- Shares outstanding 23.0M
- Free float 270K
Regnum Corp company profile
- Company name
- Regnum Corp
- Ticker
- RGMP.US
- Exchange
- USA Stocks
- Sector
- Communication Services
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 600 Third Avenue, New York, NY, United States, 10016
- Phone
- 877 313 2232
- Website
- regnumcorp.com
About Regnum Corp
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Regnum Corp management
1- Mr. Robert J. Stubblefield C.P.A.CFO & Treasurer · born 1965